Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013

  Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial
                         Results On February 26, 2013

PR Newswire

DUBLIN, Feb. 11, 2013

DUBLIN, Feb. 11, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)
today announced that it will host a conference call and live webcast on
Tuesday, February 26, 2013 at 4:30 p.m. EST/9:30 p.m. GMT.  During the call,
company management will provide a business and financial update and review its
2012 fourth quarter and full year financial results.

A live webcast of the presentation may be accessed from the Investors & Media
section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.
Please connect to the website prior to the start of the conference call to
ensure adequate time for any software downloads that may be necessary to
listen to the webcast.

Investors may participate in the conference call by dialing +1 800-920-8624 in
the U.S., or +1 617-597-5430 outside the U.S., and entering passcode 75109778.

A replay of the conference call will be available through March 5, 2013 by
dialing +1 888-286-8010 in the U.S., or +1 617-801-6888 outside the U.S., and
entering passcode 53780559.

An archived version of the webcast will be available for at least one week on
the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on
improving patients' lives by identifying, developing and commercializing
innovative products that address unmet medical needs. The company has a
diverse portfolio of products in the areas of narcolepsy, oncology, pain and
psychiatry. The company's U.S. marketed products in these areas include:
Xyrem^® (sodium oxybate) oral solution, Erwinaze^® (asparaginase Erwinia
chrysanthemi), Prialt^® (ziconotide) intrathecal infusion, Luvox CR^®
(fluvoxamine maleate), FazaClo^® (clozapine, USP) HD and FazaClo LD. Outside
of the U.S., Jazz Pharmaceuticals also has a number of products marketed by
its international division, EUSA Pharma. For further information,
see www.jazzpharmaceuticals.com.

 

 

SOURCE Jazz Pharmaceuticals plc

Website: http://www.jazzpharmaceuticals.com
Contact: Ami Knoefler, Executive Director, Investor Relations and Corporate
Communications, Jazz Pharmaceuticals plc, Ireland, + 353 1 638 1032, U.S., + 1
650 496 2947